A Phase 3 interventional study of tadalafil once a day [T(OaD)] and sildenafil citrate as needed [S(PRN)] in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 37 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 16th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2008, is one of 19 in phase 3, and was the 21st registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 378 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 13 in phase 3, and was the 16th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks
Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]
5 mg tablet taken once a day (OaD) by mouth for 8 weeks
Also known as: Cialis, LY450190
100 mg tablet taken as needed (PRN) by mouth for 8 weeks
20 mg tablet taken as needed (PRN) by mouth for 8 weeks
Also known as: Cialis, LY450190
Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)
Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
Time frame: baseline, 8 weeks of each treatment
Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
Time frame: baseline, 8 weeks of each treatment
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint
EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).
Time frame: 8 weeks of each treatment
Number of Participants With at Least One Serious Adverse Event
Serious adverse events are listed in the Reported Adverse Event module.
Time frame: baseline through 26 weeks (including two washout periods of 1 week each)
Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score
Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.
Time frame: baseline, 8 weeks of each treatment
Question 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
Scores for Question 1 range from 0 (not at all) to 4 (extremely).
Time frame: 8 weeks of each treatment
Question 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
Scores for Question 2 range from 0 (not at all) to 4 (extremely).
Time frame: 8 weeks of each treatment
Question 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
Scores for Question 3 range from 0 (not at all) to 4 (extremely).
Time frame: 8 weeks of each treatment
Question 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
Scores for Question 4 range from 0 (not at all) to 4 (extremely).
Time frame: 8 weeks of each treatment
| Milestone | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) |
|---|---|---|---|---|---|---|
| Started | 62 | 63 | 63 | 63 | 63 | 64 |
| Completed | 59 | 51 | 57 | 54 | 55 | 58 |
| Not completed | 3 | 12 | 6 | 9 | 8 | 6 |
| Withdrew: Adverse event | 0 | 2 | 0 | 2 | 1 | 1 |
| Withdrew: Serious adverse event | 1 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 | 4 | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 2 | 1 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 0 | 0 | 0 |
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] |
|---|---|---|
| Baseline | 2.24 ± 0.62 | 2.23 ± 0.63 |
| Change from Baseline | 0.50 ± 0.78 | 0.39 ± 0.67 |
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|
| Baseline | 2.24 ± 0.62 | 2.24 ± 0.63 |
| Change from Baseline | 0.50 ± 0.78 | 0.50 ± 0.72 |
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 3.06 ± 0.48 | 3.07 ± 0.48 | 3.07 ± 0.48 |
| Change from Baseline | 0.10 ± 0.50 | -0.05 ± 0.49 | 0.07 ± 0.49 |
The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 2.43 ± 0.53 | 2.42 ± 0.54 | 2.42 ± 0.53 |
| Change from Baseline | -0.30 ± 0.03 | 0.00 ± 0.53 | -0.17 ± 0.55 |
Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 15.60 ± 6.26 | 15.40 ± 6.27 | 15.55 ± 6.23 |
| Change from Baseline | 8.68 ± 6.94 | 9.70 ± 7.01 | 9.54 ± 7.00 |
| proportion of days | Tadalafil Once a Day [T(OaD)] | Tadalafil as Needed [T(PRN)] | Sildenafil as Needed [S(PRN)] |
|---|---|---|---|
| Baseline | 0.28 ± 0.26 | 0.28 ± 0.26 | 0.27 ± 0.26 |
| Change from Baseline | 0.26 ± 0.29 | 0.20 ± 0.25 | 0.11 ± 0.24 |
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 8.35 ± 2.76 | 8.34 ± 2.77 | 8.37 ± 2.73 |
| Change from Baseline | 3.33 ± 3.16 | 3.99 ± 3.17 | 3.83 ± 3.13 |
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 5.26 ± 2.34 | 5.22 ± 2.36 | 5.27 ± 2.34 |
| Change from Baseline | 2.60 ± 2.61 | 2.87 ± 2.55 | 2.84 ± 2.58 |
EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint | 75.81 ± 22.36 | 75.68 ± 19.58 | 79.50 ± 19.56 |
Serious adverse events are listed in the Reported Adverse Event module.
| participants | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Number of Participants With at Least One Serious Adverse Event | 4 | 5 | 2 |
Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Baseline | 50.28 ± 21.36 | 50.50 ± 21.58 | 50.69 ± 21.32 |
| Change from Baseline | 22.94 ± 24.86 | 22.87 ± 24.43 | 24.13 ± 24.53 |
Scores for Question 1 range from 0 (not at all) to 4 (extremely).
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Question 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint | 1.83 ± 1.25 | 1.78 ± 1.13 | 1.77 ± 1.22 |
Scores for Question 2 range from 0 (not at all) to 4 (extremely).
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Question 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint | 2.33 ± 1.09 | 2.14 ± 1.01 | 2.36 ± 1.10 |
Scores for Question 3 range from 0 (not at all) to 4 (extremely).
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Question 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint | 1.99 ± 1.19 | 2.28 ± 1.12 | 2.50 ± 1.14 |
Scores for Question 4 range from 0 (not at all) to 4 (extremely).
| units on a scale | Tadalafil Once a Day [T(OaD)] | Sildenafil as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| Question 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint | 2.53 ± 1.10 | 2.57 ± 1.06 | 2.44 ± 0.99 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil Once a Day [T(OaD)] | — | 4/378 (1.1%) | 66/378 (17.5%) |
| Sildenafil Citrate as Needed [S(PRN)] | — | 5/378 (1.3%) | 73/378 (19.3%) |
| Tadalafil as Needed [T(PRN)] | — | 2/378 (0.5%) | 70/378 (18.5%) |
| Event | Tadalafil Once a Day [T(OaD)] | Sildenafil Citrate as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/378 | 1/378 | 0/378 |
| Coronary artery occlusionCardiac disorders | 0/378 | 1/378 | 0/378 |
| Myocardial infarctionCardiac disorders | 0/378 | 0/378 | 1/378 |
| Retinal detachmentEye disorders | 1/378 | 0/378 | 0/378 |
| FallInjury, poisoning and procedural complications | 1/378 | 0/378 | 0/378 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/378 | 1/378 | 0/378 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/378 | 1/378 | 0/378 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/378 | 0/378 | 1/378 |
| Elbow operationSurgical and medical procedures | 0/378 | 1/378 | 0/378 |
| Event | Tadalafil Once a Day [T(OaD)] | Sildenafil Citrate as Needed [S(PRN)] | Tadalafil as Needed [T(PRN)] |
|---|---|---|---|
| HeadacheNervous system disorders | 10/378 | 13/378 | 8/378 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 5/378 | 8/378 | 3/378 |
| FlushingVascular disorders | 6/378 | 8/378 | 3/378 |
| DyspepsiaGastrointestinal disorders | 6/378 | 5/378 | 4/378 |
| Back painMusculoskeletal and connective tissue disorders | 3/378 | 3/378 | 5/378 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/378 | 0/378 | 1/378 |
| DiarrhoeaGastrointestinal disorders | 3/378 | 4/378 | 2/378 |
| HypertensionVascular disorders | 2/378 | 2/378 | 4/378 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/378 | 3/378 | 2/378 |
| Lower respiratory tract infectionInfections and infestations | 2/378 | 3/378 | 2/378 |
| Age Continuous(years) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 58.53 ± 11.62 | 55.12 ± 8.89 | 55.40 ± 11.70 | 54.87 ± 12.04 | 59.04 ± 10.56 | 54.36 ± 10.28 | 56.21 ± 10.98 |
| Sex: Female, Male(Participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 62 | 63 | 63 | 63 | 63 | 64 | 378 |
| Race/Ethnicity, Customized(participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| African | 1 | 1 | 1 | 4 | 3 | 2 | 12 |
| Caucasian | 41 | 44 | 46 | 41 | 43 | 40 | 255 |
| East Asian | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
| Hispanic | 19 | 17 | 15 | 18 | 17 | 19 | 105 |
| Native American | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| West Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Australia | 3 | 4 | 5 | 4 | 4 | 4 | 24 |
| Germany | 7 | 6 | 6 | 7 | 7 | 7 | 40 |
| Italy | 5 | 5 | 4 | 6 | 4 | 5 | 29 |
| Mexico | 14 | 14 | 14 | 14 | 14 | 14 | 84 |
| Spain | 10 | 10 | 10 | 9 | 9 | 9 | 57 |
| United Kingdom | 6 | 8 | 7 | 7 | 8 | 8 | 44 |
| United States | 17 | 16 | 17 | 16 | 17 | 17 | 100 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.35 ± 4.18 | 27.62 ± 2.65 | 27.77 ± 3.71 | 28.68 ± 4.74 | 27.80 ± 3.51 | 29.08 ± 4.26 | 28.22 ± 3.91 |
| Erectile Dysfunction (ED) Duration(participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| => 1 year | 59 | 61 | 58 | 58 | 61 | 59 | 356 |
| => than 6 months through <1 year | 3 | 2 | 5 | 5 | 2 | 5 | 22 |
| ED Etiology(participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Mixed | 25 | 26 | 21 | 23 | 23 | 28 | 146 |
| Organic | 22 | 28 | 29 | 29 | 30 | 25 | 163 |
| Psychogenic | 5 | 3 | 9 | 9 | 1 | 7 | 34 |
| Unknown | 10 | 6 | 4 | 2 | 9 | 4 | 35 |
| Prior sildenafil citrate use as needed (PRN)(participants) | T(OaD)/S(PRN)/T(PRN) | T(OaD)/T(PRN)/S(PRN) | S(PRN)/T(OaD)/T(PRN) | S(PRN)/T(PRN)/T(OaD) | T(PRN)/T(OaD)/S(PRN) | T(PRN)/S(PRN)/T(OaD) | Total |
|---|---|---|---|---|---|---|---|
| Yes | 36 | 40 | 40 | 39 | 39 | 35 | 229 |
| No | 26 | 23 | 23 | 24 | 24 | 29 | 149 |
1 further baseline measures are reported on the registry.
The record gives a start of Aug 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil